Samlyn Capital LLC raised its holdings in Allergan PLC. (NYSE:AGN) by 14.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 267,467 shares of the company’s stock after acquiring an additional 34,587 shares during the period. Allergan PLC. comprises about 1.6% of Samlyn Capital LLC’s investment portfolio, making the stock its 18th largest holding. Samlyn Capital LLC owned about 0.08% of Allergan PLC. worth $65,018,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of AGN. Howard Hughes Medical Institute bought a new stake in shares of Allergan PLC. in the second quarter valued at about $103,000. Jacobi Capital Management LLC lifted its holdings in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares in the last quarter. JNBA Financial Advisors lifted its holdings in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after purchasing an additional 12 shares in the last quarter. Massey Quick & Co. LLC lifted its holdings in shares of Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares in the last quarter. Finally, Pacific Center for Financial Services lifted its holdings in shares of Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after purchasing an additional 475 shares in the last quarter. 82.04% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2957250/allergan-plc-agn-shares-bought-by-samlyn-capital-llc.html.
Shares of Allergan PLC. (NYSE AGN) opened at 204.08 on Friday. The company has a market cap of $68.23 billion, a price-to-earnings ratio of 6.22 and a beta of 1.15. The company’s 50-day moving average price is $216.44 and its 200 day moving average price is $232.29. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter last year, the firm earned $3.35 EPS. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. Equities analysts predict that Allergan PLC. will post $16.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.37%. Allergan PLC.’s dividend payout ratio is currently 9.95%.
Allergan PLC. announced that its board has approved a share repurchase program on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.
AGN has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on Allergan PLC. in a report on Friday, June 16th. They issued a “neutral” rating and a $231.00 price target on the stock. BidaskClub upgraded Allergan PLC. from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. Vetr lowered Allergan PLC. from a “buy” rating to a “hold” rating and set a $234.38 price target on the stock. in a report on Monday, June 19th. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target on the stock in a report on Tuesday, July 11th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $231.00 price target on shares of Allergan PLC. in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of “Buy” and an average target price of $271.64.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.